XM does not provide services to residents of the United States of America.
G
G

Groupon


News

U.S. STOCKS Kraft Heinz, Marriott, Mastercard

BUZZ-U.S. STOCKS ON THE MOVE-Kraft Heinz, Marriott, Mastercard Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 jumped around 2% on Wednesday, as investors hoped for hints from the Federal Reserve on the timing of rate cuts, a bullish forecast from AMD boosted chip stocks and Microsoft slipped after a higher spending forecast.
B
B
D
G
I
M
M
M
N
S
V
A
K
T
U
U
G
U
W
A
B

U.S. STOCKS Microsoft, Boeing, Uber

BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Boeing, Uber Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 were poised to open sharply higher on Wednesday after a bullish forecast from AMD boosted struggling chip stocks, while Microsoft faltered among megacaps ahead of an interest-rate decision from the Federal Reserve.
B
B
D
G
I
M
N
S
A
T
U
U
U

Groupon slides after wider loss in Q2

BUZZ-Groupon slides after wider loss in Q2 ** Groupon's GRPN.O shares down 3.8% at $15.11, after being down more than 15% premarket, after daily deals platform reported wider qtrly loss ** Co late Tues posted Q2 net loss of $10 mln, or 25 cents/sh, compared to loss of $12.6 mln, or 41 cents/sh, a yr ago ** Analysts expected profit of 2 cents in the qtr, per LSEG ** Rev in qtr fell ~3% yr/yr to $124.6 mln, above consensus view of $121.7 mln ** Co said after a careful review it's exiting its local
G

Groupon Q2 Revenue USD 124.6 Million

BRIEF-Groupon Q2 Revenue USD 124.6 Million Jul 30 (Reuters) - Groupon Q2 adjusted EBITDA USD 16.5 million. Q2 gross profit USD 112.7 million Q2 net income USD -9.4 million
G

Groupon Inc <GRPN.OQ> expected to post earnings of 2 cents a share - Earnings Preview

Groupon Inc expected to post earnings of 2 cents a share - Earnings Preview Groupon Inc GRPN.OQ GRPN.O is expected to show a fall in quarterly revenue when it reports results on July 30 for the period ending January 1 0001 The Chicago Illinois-based company is expected to report a 5.7% decrease in revenue to $121.737 million from $129.11 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on May 9 2024, for the period ended June 30, was
G

Tempus AI stretches rally as co and SoftBank launch AI healthcare JV

BUZZ-Tempus AI stretches rally as co and SoftBank launch AI healthcare JV ** Shares of genetics testing firm Tempus AI TEM.O , backed by SoftBank 9984.T , up ~7% early Thurs, adding to ~10% gain in prior session ** SoftBank has launched joint venture with Tempus aiming to analyze personal medical data with artificial intelligence to come up with treatment recommendations, CEO Masayoshi Son told a briefing in Tokyo on Thurs ** The cos expected to each put $93 mln into the JV, which is anticipated
G

SoftBank-backed Tempus AI sinks to new post-IPO lows

BUZZ-SoftBank-backed Tempus AI sinks to new post-IPO lows ** Shares of Tempus AI TEM.O , genetics testing firm backed by SoftBank 9984.T , down 2.7% at $24.63 on Tues and now off ~33% from IPO price ** Stock drops as much as 9.6% to $22.89 on the session ** TEM shares on track to fall for fifth time in past six days since closing up nearly 9% at $40.25 in their Jun 14 debut ** Tempus, founded in 2015 and has yet to turn a profit, raised ~$411 mln by selling 11.1 mln shares at $37 , top end of ma
G

SoftBank-backed Tempus AI extends slump after strong listing

BUZZ-SoftBank-backed Tempus AI extends slump after strong listing Updates ** Shares of SoftBank 9984.T -backed Tempus AI TEM.O tumble as much as ~ 21 % to slump for the third straight session ** The genetics testing firm, led by Groupon GRPN.O co-founder Eric Lefkofsky, closed up 8.8% at $40.25 on its market debut on Friday, June 14 ** Shares fell 9.4% on Monday and 16.9% on Tuesday ** Tempus, which was founded in 2015 and is yet to post a profit, raised $410.7 mln by selling 11.1 mln shares at
G

SoftBank-backed Tempus AI extends slump after strong listing

BUZZ-SoftBank-backed Tempus AI extends slump after strong listing ** Shares of SoftBank 9984.T -backed Tempus AI TEM.O tumble as much as 20% to slump for the third straight session ** The genetics testing firm, led by Groupon GRPN.O co-founder Eric Lefkofsky, closed up 8.8% at $40.25 on its market debut on Friday, June 14 ** Shares fell 9.4% on Mon
G

SoftBank-backed Tempus AI tumbles well below IPO price

BUZZ-SoftBank-backed Tempus AI tumbles well below IPO price ** Shares of Tempus AI TEM.O , genetics testing firm backed by SoftBank 9984.T , down 16% at $30.65 on Tues in their third day of trading ** TEM, which shed ~9% on Mon, tumbles as low as $30.31 on the session ** Stock now >17% below $37 IPO price set late Thurs after co raised ~$411 mln by selling 11.1 mln shares ** TEM traded as high as $43.88 in debut on Fri before closing at $40.25 ** Co led by Groupon GRPN.O co-founder Eric Lefkofsk
G

IBM settles lawsuit against Rakuten over e-commerce patents

IBM settles lawsuit against Rakuten over e-commerce patents By Blake Brittain June 17 (Reuters) - International Business Machines Corp IBM.N has settled a lawsuit accusing Japan's Rakuten 4755.T of infringing IBM patents related to e-commerce technology, Delaware federal court records showed on Monday. U.S. District Judge Gregory Williams said in an oral order that he was "pleased to hear that the parties have reached an agreement to settle this case," according to an entry on the court's docket
G

Tempus AI prices US IPO at over $6 bln valuation

UPDATE 1-Tempus AI prices US IPO at over $6 bln valuation Updates with details in paragraph 2,3 and background in paragraph 4,5 June 13 (Reuters) - SoftBank Group-backed 9984.T Tempus AI set the pricing of its U.S. initial public offering at $37 per share on Thursday, aiming to raise $410.7 million. The genetics-testing company priced its IPO at the higher end of is targeted range of $35 to $37, valuing the firm at about $6.10 billion, based on the outstanding shares listed in its filing with th
G

SoftBank-backed Tempus AI seeks up to $6.1 bln valuation in US IPO

UPDATE 2-SoftBank-backed Tempus AI seeks up to $6.1 bln valuation in US IPO Adds background and details on competitors, customers and funding in paragraphs 4-10 June 5 (Reuters) - Tempus AI, backed by Japanese tech investment firm SoftBank Group 9984.T , is targeting a valuation of up to $6.10 billion for its U.S. initial public offering, nearly three years after the genetics-testing company laid the ground for its listing.
A
G
G
R
V

Precision-medicine IPO deserves Groupon discount

BREAKINGVIEWS-Precision-medicine IPO deserves Groupon discount The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, May 31 (Reuters Breakingviews) - Personalized cancer treatments developed using genetic data crunched by artificial intelligence under the watch of a board that includes a Nobel laureate is the sort of business that should be an easy sell in today’s stock market.
G



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.